Hims & Hers
Hims & Hers scored 48/100 on Panya's 11-signal vendor rubric. Each signal is scored 0 to 100, the methodology is public, and our affiliate posture is flat-fee · never pay-to-rank. Below is the full per-signal breakdown.
- COA on every lotCompounded supply chain documented in Sept 9, 2025 FDA Warning Letter to Hers; transitioning to brand mid-202650
- Cold-chain verified60
- Rx legalitySept 9, 2025 FDA Warning Letter (Hers · misleading compounded-semaglutide marketing); Feb 9, 2026 Novo Nordisk patent-infringement lawsuit (US 8,129,343, alleges 'inauthentic API'). April 30, 2026 503B-exclusion proposal materially closes the compounded path entirely35
- Compound identityNovo lawsuit specifically alleges 'inauthentic API' in Hims-supplied compounded semaglutide45
- Dose accuracy60
- Endotoxin testing55
- Refund posture60
- Channel clarityPublic March 2026 announcement of Novo brand-semaglutide integration is the right pivot, but execution mid-flight; legacy compounded supply still active during transition window50
- Support quality65
- Price transparencyCompounded pricing well below brand; brand-pivot pricing tier not fully published65
- Longitudinal retentionPublic-company scale (~2M+ subscribers) but legal + regulatory overhang deeply concentrated. Hold until brand-pivot completes and Novo suit resolves40
Brand pharmacy supply stable. Compounded channel sunsetting · April 30, 2026 FDA proposal to exclude tirzepatide from the 503B bulks list (comment closes June 29, final rule likely Q3 2026) closes the mass-compounded path. 503A patient-specific compounding survives only with documented medical necessity. Telehealth platforms (Hims, Ro, Mochi) pivoting toward brand prescriptions or oral alternatives.
Recovered from the 2023 shortage. Diabetes-coded insurance straightforward.
Oral semaglutide. Niche fit for needle-averse patients. Lower bioavailability than injectable.
Recovered from the 2023-24 shortage. Insurance coverage expanding under 2025-26 employer plans. Oral Wegovy 25mg launched Jan 2026 at $149/mo · adds a needle-free path. Compounded semaglutide channel similarly narrowing under post-Feb-2025 enforcement-discretion rules.
Lilly-direct LillyDirect channel (US-only) supplements pharmacy distribution. Stable. Brand-channel demand expected to lift through 2026 as compounded pathway closes under the April 30 FDA 503B-exclusion proposal · LillyDirect's at-launch pricing materially undercuts compounded for patients without insurance coverage.
- FDA · Warning Letter to Hims & Hers Health, Inc. dba Hers (September 9, 2025)
- Novo Nordisk patent infringement complaint against Hims & Hers (February 9, 2026)
- FDA · April 30, 2026 proposal to exclude tirzepatide from 503B bulks list
- Hims & Hers Q4 2025 / Q1 2026 investor updates (brand-semaglutide integration announcement)
The 11-signal rubric is public.
Identity, dose accuracy, COA, cold-chain, Rx legality, compound identity, endotoxin testing, refund posture, channel clarity, support quality, price transparency, longitudinal retention. Each scored 0 to 100. Vendors that fail our floor are silently filtered out · they don't appear in our match flow at all.
If Hims & Hers wants to dispute or update this score, contact partner@panya.health. Score updates are recorded on this page with a public changelog.
Want a match for your situation?
Take the 2-minute quiz. We'll match you against this and the other vendors in your region · based on your dose, urgency, and budget.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.